129 related articles for article (PubMed ID: 25140627)
1. Targeting the androgen receptor signaling axis to reduce testosterone levels in prostate cancer: how low should we go?
Cheng HH; Higano CS
Oncology (Williston Park); 2014 Aug; 28(8):700-1. PubMed ID: 25140627
[No Abstract] [Full Text] [Related]
2. The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer.
Moul JW
Oncology (Williston Park); 2014 Aug; 28(8):702-3, 722. PubMed ID: 25140628
[No Abstract] [Full Text] [Related]
3. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
Bastos DA; Dzik C; Rathkopf D; Scher HI
Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
[TBL] [Abstract][Full Text] [Related]
4. [Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer].
Hu YH; Guo JC; Zhang M
Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1138-1140. PubMed ID: 29738189
[TBL] [Abstract][Full Text] [Related]
5. Targeting androgen-independent pathways: new chances for patients with prostate cancer?
Cattrini C; Zanardi E; Vallome G; Cavo A; Cerbone L; Di Meglio A; Fabbroni C; Latocca MM; Rizzo F; Messina C; Rubagotti A; Barboro P; Boccardo F
Crit Rev Oncol Hematol; 2017 Oct; 118():42-53. PubMed ID: 28917268
[TBL] [Abstract][Full Text] [Related]
6. [ASC-J9 for castration-resistant prostate cancer].
Yamashita S; Arai Y
Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
[TBL] [Abstract][Full Text] [Related]
7. Leading causes of castration-resistant prostate cancer.
Lu M; Lu H; Kong Q
Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
Coutinho I; Day TK; Tilley WD; Selth LA
Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
[TBL] [Abstract][Full Text] [Related]
9. [Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer].
Küronya Z; Bíró K; Gyergyay F; Géczi L
Orv Hetil; 2017 Jan; 158(2):42-49. PubMed ID: 28088885
[TBL] [Abstract][Full Text] [Related]
10. The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications.
Kumar R; Sena LA; Denmeade SR; Kachhap S
Nat Rev Urol; 2023 May; 20(5):265-278. PubMed ID: 36543976
[TBL] [Abstract][Full Text] [Related]
11. Can progressive site-directed therapy prolong the efficacy of subsequent androgen receptor axis-targeted drugs in oligometastatic castration-resistant prostate cancer?
Yoshida S; Takahara T; Yokoyama M; Matsuoka Y; Yoshimura R; Fujii Y
Int J Urol; 2021 Feb; 28(2):241-242. PubMed ID: 33140442
[No Abstract] [Full Text] [Related]
12. How quality of life can help guide selection of androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.
Smith MR
Clin Adv Hematol Oncol; 2021 Oct; 19(10):627-630. PubMed ID: 34637427
[No Abstract] [Full Text] [Related]
13. Clinical observations regarding the use of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Oh WK
Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):13-16. PubMed ID: 35579580
[No Abstract] [Full Text] [Related]
14. Prognosis of metastatic castration-resistant prostate cancer in the era of the second-generation androgen receptor-targeted agents: A retrospective multicenter study.
Iwamura H; Hatakeyama S; Narita S; Arai Y; Habuchi T; Ohyama C
Int J Urol; 2021 Jan; 28(1):125-127. PubMed ID: 33034051
[No Abstract] [Full Text] [Related]
15. Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A.
Oh WK; Rettig MB
Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):16-17. PubMed ID: 35579581
[No Abstract] [Full Text] [Related]
16. How patient characteristics can guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Rettig MB
Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):9-12. PubMed ID: 35579579
[No Abstract] [Full Text] [Related]
17. Does degree of androgen suppression matter in hormone-sensitive prostate cancer?
Suzman DL; Antonarakis ES
J Clin Oncol; 2015 Apr; 33(10):1098-100. PubMed ID: 25732171
[No Abstract] [Full Text] [Related]
18. Microenvironment-Mediated Resistance to Anti-Androgen Therapy.
Orme JJ; Huang H
Cancer Cell; 2020 Aug; 38(2):155-157. PubMed ID: 32781041
[TBL] [Abstract][Full Text] [Related]
19. Targeting the mechanisms of progression in castration-resistant prostate cancer.
Ceder JA
Eur Urol; 2015 Mar; 67(3):480-1. PubMed ID: 25465967
[No Abstract] [Full Text] [Related]
20. Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide as the first androgen receptor inhibitor in a fit, older man.
Lowentritt BH
Clin Adv Hematol Oncol; 2022 Jan; 20 Suppl 1(1):1-8. PubMed ID: 35343943
[No Abstract] [Full Text] [Related]
[Next] [New Search]
